Sensifree News
6 articles
growth-positive
https://www.jpost.com/jpost-tech/bird-to-invest-6m-in-joint-us-israel-innovation-projects-674225
The BIRD Foundation has announced collaborations between US and Israeli companies in various technological sectors for joint product development. The projects include the development of an operational cyber threat intelligence capability, a platform for enrolling diverse patients in clinical trials, personalized self neuro-modulation therapy for major depression disorders, a LEO Satellite End-User Mobile Terminal, and next-generation non-invasive blood pressure monitors. The projects will receive grants from the BIRD Foundation, with private sector funding also contributing to a total project value of $13 million. The BIRD Foundation has a history of funding joint projects, with a total investment of over $370 million to date. The deadline for submission of Executive Summaries for the next BIRD cycle is September 2, 2021.
PartnersInvestment
growth-positive
Sensifree and Dreamtech Partner on Product Development Supported by the KORIL-RDF Foundation
Sensifree LTD and Dreamtech Co., LTD have launched a joint development program to develop non-invasive blood pressure and vital signs monitoring solutions for professional use. The program is supported by the Korea-Israel Research and Development Foundation. The purpose of the grant is to develop commercial products for continuous monitoring of blood pressure and other vital signs in hospitals and clinical settings. The collaboration aims to improve quality of care, patient safety, and medical outcomes. Sensifrees technology and Dreamtechs commercialization capabilities will be utilized in the development of these products. The program is seen as a major milestone for Sensifree as they move towards regulatory clearance and market entry.
Partners
growth-positive
Sensifree Named Winner of 2018 Red Herring Top 100 North America Award Taiwan News 2018-07-10 19:01:30
Sensifree, a medical device company, has been chosen as a winner of the Red Herring Top 100 North America 2018 award. The company is developing advanced RF-based hemodynamic monitoring solutions, including a blood pressure monitoring solution for critical care settings. Sensifrees innovative technology allows for continuous blood pressure monitoring without the need for an invasive arterial line. The companys first product, a blood pressure monitor, aims to increase patient safety by better monitoring during surgery. Sensifree was recognized for its financial performance, innovation, business strategy, and market penetration.
Partners
Sensifree Reports Statistically Significant Concordance of Arterial Pressure Signal Waveform Between its Continuous Non-invasive Blood Pressure Monitoring Technology and Invasive Arterial Line
growth-positive
CSEM And Sensifree Announce Research Partnership
Sensifree and CSEM have announced a research partnership to develop a cuff-free blood pressure sensor technology for the health wearables market. Sensifrees RF-based sensors aim to provide an alternative to traditional blood pressure monitoring technologies. The collaboration with CSEM, known for its expertise in non-obtrusive blood pressure estimation, will help Sensifree further explore this technology and create a reliable and ultra-low-power solution for the wearables market.
Partners
growth-positive
Israeli biometric sensing co Sensifree raises $5m
Israeli startup Sensifree has completed a $5 million Series A financing round led by TransLink Capital. The funding will be used to expand the companys engineering and product development teams and accelerate its business development efforts. Sensifree is developing low power, contact-free, electromagnetic sensors for wearable devices in the healthcare market. The companys first product is a contactless heart rate sensor for wearable devices, and they are also working on a cuff-free blood pressure sensor. Sensifree aims to provide a better alternative to traditional sensor technologies. The funding brings Sensifrees total funding to $7 million.
InvestmentExpand
